查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1391912

硫酸新斯的明注射液市场：按剂量、适应症、按通路、按最终用途、按地区

Neostigmine Methylsulfate Injection Market, By Dosage, By Indication, By Distribution Channel, By End Use, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

甲基硫酸新斯的明注射液的全球市场规模预计到2023年为1.567亿美元，预计到2030年将达到2.133亿美元，预测期内复合年增长率为4.5%。

报告范围 报告详情
基准年 2022年 2023年市场规模 1.567 亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 4.50% 2030年市场规模预测 2.133 亿美元
图1. 2023年甲基硫酸新斯的明注射液按地区分類的全球市场占有率（%）
甲基硫酸新斯的明注射液市场-IMG1

甲基硫酸新斯的明注射液是一种胆碱酯酶抑制剂，用作治疗重症肌无力的辅助药物，也可作为手术室和加护病房非去极化神经肌肉阻断剂毒性的解毒剂。该药物透过抑制乙酰胆碱酯酶而发挥作用，乙酰胆碱酯酶会分解神经肌肉接头处的神经肌肉传导物质乙酰胆碱。透过抑制这种酶，甲基硫酸新斯的明可以延长乙酰胆碱的作用，并增加神经肌肉传递和肌肉力量。它可用于治疗重症肌无力的症状，例如四肢、身体躯干、喉咙、眼睛等骨骼肌的肌肉无力。如果服用给药或过敏的患者，神经肌肉接头的刺激可能会增加，引起噁心、流涎增加和肌肉痉挛等副作用。

市场动态：

在预测期内，老年人口的增加也可能推动全球硫酸新斯的明注射液市场的成长。老年人更容易患重症肌无力等神经系统疾病，通常需要注射甲基硫酸新斯的明来治疗。在预测期内，医疗保健成本的上升也可能继续推动全球硫酸新斯的明注射液市场的成长。在预测期内，兽药的成长可能为全球硫酸新斯的明注射液市场创造新的机会。甲基硫酸新斯的明注射液也用于兽医，特别是用于治疗动物的多种神经肌肉疾病。增加甲基硫酸新斯的明注射液在兽医行业的使用和可得性可能会开闢新的商业性前景。

缺乏知识和诊断预计将阻碍预测期内全球硫酸新斯的明注射液市场的成长。

本研究的主要特点

  • 本报告对全球甲基硫酸新斯的明注射液市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率（CAGR%）。
  • 它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球甲基硫酸新斯的明注射液市场的主要参与者进行了分析。
  • 本研究涵盖的主要企业包括 Baxter International Inc.、Pfizer Inc.、Fresenius Kabi AG、Boehringer Ingelheim GmbH、Mylan NV、Novartis International AG、Teva Pharmaceutical Industries Ltd.、Hikma Pharmaceuticals PLC、、GlaxoSmithKline plclc、Sun Industries Ltd.、Hikma Pharmaceuticals PLC、、GlaxoSmithKline plclc、Sun Industries Ltd.、Hikma Pharmaceuticals PLC、、GlaxoSmithKline plclc、Sun Industries Ltd.、Hikma Pharmaceuticals PLC、、GlaxoSmithKline plclc. Ltd.、Sandoz（诺华公司的子公司）、Accord Healthcare Inc.、Lannett Company, Inc.、Mallinckrodt Pharmaceuticals 和Lupin Limited。
  • 从这份报告中获得的见解将帮助行销人员和经营团队就未来的产品发布、升级、市场扩张和行销策略负责人资讯的决策。
  • 全球甲基硫酸新斯的明注射液市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
  • 透过用于分析全球硫酸新斯的明注射液市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 促进因素
  • 需要新斯的明的重症肌无力和术后肠阻塞等疾病的盛行率增加
  • 抑制因素
  • 缺乏知识和诊断
  • 机会
  • 兽医医学的发展
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章全球硫酸新斯的明注射液市场-冠状冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章2018-2030年全球硫酸甲酯新斯的明注射液市场（按剂量）

  • 介绍
  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 1mg/mL
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • mg/mL
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第六章2018-2030年全球硫酸甲酯新斯的明注射液市场（依适应症）

  • 介绍
  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 重症肌无力
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 神经肌肉阻断的逆转
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第7章2018-2030年全球甲基硫酸新斯的明注射液市场（依配销通路）

  • 介绍
  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 医院药房
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 零售药房
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 线上药房
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第8章2018-2030年全球硫酸甲酯新斯的明注射液市场（依最终用户划分）

  • 介绍
  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 医院
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 专科诊所
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 门诊手术中心
  • 介绍
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第9章2018-2030年全球硫酸甲酯新斯的明注射液市场（分地区）

  • 介绍
  • 2023 年及 2030 年按地区分類的市场占有率分析 (%)
  • 2019-2030 年地区与前一年同期比较成长分析
  • 各国的趋势
  • 北美洲
  • 介绍
  • 2018-2030 年市场规模与剂量预测、与前一年同期比较成长率
  • 2018-2030年市场规模及依指标预测、与前一年同期比较成长率
  • 2018-2030年按配销通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 美国
  • 加拿大
  • 欧洲
  • 介绍
  • 2018-2030 年市场规模与剂量预测、与前一年同期比较成长率
  • 2018-2030年市场规模及依指标预测、与前一年同期比较成长率
  • 2018-2030年按配销通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 介绍
  • 2018-2030 年市场规模与剂量预测、与前一年同期比较成长率
  • 2018-2030年市场规模及依指标预测、与前一年同期比较成长率
  • 2018-2030年按配销通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 中国
  • 印度
  • 日本
  • 东南亚国协
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 介绍
  • 2018-2030 年市场规模与剂量预测、与前一年同期比较成长率
  • 2018-2030年市场规模及依指标预测、与前一年同期比较成长率
  • 2018-2030年按配销通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东和非洲
  • 介绍
  • 2018-2030 年市场规模与剂量预测、与前一年同期比较成长率
  • 2018-2030年市场规模及依指标预测、与前一年同期比较成长率
  • 2018-2030年按配销通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 北非
  • 中部非洲
  • 南非

第10章竞争形势

  • Baxter International Inc.
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Boehringer Ingelheim GmbH
  • Mylan NV
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz（a division of Novartis）
  • Accord Healthcare Inc.
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Lupin Limited

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6033

The global neostigmine methylsulfate injection market size is projected to be valued at US$ 156.7 Mn in 2023 and is projected to reach US$ 213.3 Mn by 2030, registering a CAGR of 4.5% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 156.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.50% 2030 Value Projection: US$ 213.3 Mn
Figure 1. Global Neostigmine Methylsulfate Injection Market Share (%), by Region, 2023
Neostigmine Methylsulfate Injection Market - IMG1

Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.

Market Dynamics:

The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.

Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.

Key Features of the Study:

  • This report provides an in-depth analysis of the global neostigmine methylsulfate injection market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market

Detailed Segmentation:

  • Global Neostigmine Methylsulfate Injection Market, By Dosage:
    • 1 mg/mL
    • 0.5 mg/mL
  • Global Neostigmine Methylsulfate Injection Market, By Indications:
    • Myasthenia Gravis
    • Reversal of Neuromuscular Blockade
  • Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Neostigmine Methylsulfate Injection Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Global Neostigmine Methylsulfate Injection Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profile:
    • Baxter International Inc.
    • Pfizer Inc.
    • Fresenius Kabi AG
    • Boehringer Ingelheim GmbH
    • Mylan N.V.
    • Novartis International AG
    • Teva Pharmaceutical Industries Ltd.
    • Hikma Pharmaceuticals PLC
    • GlaxoSmithKline plc
    • Sun Pharmaceutical Industries Ltd.
    • Sandoz (a division of Novartis)
    • Accord Healthcare Inc.
    • Lannett Company, Inc.
    • Mallinckrodt Pharmaceuticals
    • Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Neostigmine Methylsulfate Injection Market, By Dosage
    • Neostigmine Methylsulfate Injection Market, By Indication
    • Neostigmine Methylsulfate Injection Market, By Distribution Channel
    • Neostigmine Methylsulfate Injection Market, By End User
    • Neostigmine Methylsulfate Injection Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
  • Restraints
  • Lack of knowledge and diagnosis
  • Opportunities
  • Growth of veterinary medicine
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Neostigmine Methylsulfate Injection Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2018-2030, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • 1 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • 0.5 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2018-2030, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Myasthenia Gravis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Reversal of Neuromuscular Blockade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

8. Global Neostigmine Methylsulfate Injection Market, By End User, 2018-2030, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

9. Global Neostigmine Methylsulfate Injection Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region 2019 - 2030
  • Country Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
  • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Fresenius Kabi AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Hikma Pharmaceuticals PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Sandoz (a division of Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Accord Healthcare Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Lannett Company, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us